Australia is closely awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://giantcyclingbike493480.newsyblog.com/805497/novo-nordisk-s-retatrutide-australia-a-promising-hope-for-obesity-treatment